S
Stina M. Singel
Researcher at Genentech
Publications - 29
Citations - 2275
Stina M. Singel is an academic researcher from Genentech. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 12, co-authored 25 publications receiving 1390 citations. Previous affiliations of Stina M. Singel include Stanford University & University of Texas Southwestern Medical Center.
Papers
More filters
Journal ArticleDOI
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
Gunter von Minckwitz,Chiun Sheng Huang,Max S. Mano,Sibylle Loibl,Eleftherios P. Mamounas,Michael Untch,Norman Wolmark,P Rastogi,Andreas Schneeweiss,Andrés Redondo,Hans Holger Fischer,William Jacot,Alison Conlin,Claudia Arce-Salinas,Irene Wapnir,Christian Jackisch,Michael P. DiGiovanna,Peter A. Fasching,John Crown,Pia Wülfing,Zhimin Shao,Elena Rota Caremoli,Haiyan Wu,Lisa H. Lam,David Tesarowski,Melanie C. Smitt,Hannah Douthwaite,Stina M. Singel,Charles E. Geyer +28 more
TL;DR: Among patients with HER2‐positive early breast cancer who had residual invasive disease after completion of neoadjuvant therapy, the risk of recurrence of invasive breast cancer or death was 50% lower with adjuvant T‐DM1 than with trastuzumab alone.
Journal ArticleDOI
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Sung Bae Kim,Rebecca Dent,Seock-Ah Im,Marc Espié,Sibel Blau,Antoinette R Tan,Steven J Isakoff,Mafalda Oliveira,Cristina Saura,Matthew Wongchenko,Amy V. Kapp,Wai Y. Chan,Stina M. Singel,Daniel J Maslyar,José Baselga,Keun Seok Lee,Hwei Chung Wang,Antoinette R. Tan,Joohyuk Sohn,Michelino De Laurentiis,Laura G. Estévez,Chiun-Sheng Huang,Gilles Romieu,Michel Velez,Rafael Villanueva,Pierfranco Conte,Shaker R. Dakhil,Marc Debled,Antonio Gonzalez Martin,Sara A. Hurvitz,Jee Hyun Kim,Christelle Levy,Pedro Sánchez Rovira,Jae Hong Seo,Vicente Valero,Gregory Vidal,Andrea Wong,Mary Ann K Allison,Robert A. Figlin,David Chan,Shin-Cheh Chen,Yen-Hsun Chen,Melody A. Cobleigh,Filippo de Braud,Luc Dirix,Vincent Hansen,Anne Hardy Bessard,Nicholas Iannotti,Steven J. Isakoff,William E. Lawler,Alvaro Montaño,Mohamad Salkini,Leonard Seigel +52 more
TL;DR: These are the first results supporting AKT-targeted therapy for triple-negative breast cancer and Ipatasertib warrants further investigation for the treatment of triple- negative breast cancer.
Journal ArticleDOI
FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer
Mafalda Oliveira,Mafalda Oliveira,Cristina Saura,Cristina Saura,P. Nuciforo,Isabel Calvo,Jay Andersen,José Luís Passos-Coelho,M. Gil Gil,Begoña Bermejo,Debra A. Patt,Eva Ciruelos,L de la Pena,N. Xu,Matthew Wongchenko,Zhen Shi,Stina M. Singel,Steven J. Isakoff +17 more
TL;DR: Adding ipatasertib to 12 weeks of paclitaxel for early TNBC did not clinically or statistically significantly increase pCR rate, although overall response rate by MRI was numerically higher with ipat asertib.
Journal ArticleDOI
Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study
Peter Vuylsteke,Manon T. Huizing,Katarína Petráková,Rebecca Roylance,Robert W. Laing,Stephen Chan,F. Abell,Steven Gendreau,Isabelle Rooney,D. Apt,J. Zhou,Stina M. Singel,Louis Fehrenbacher +12 more
TL;DR: PEGGY did not meet its primary end point, revealing no significant benefit from adding pictilisib to paclitaxel for patients with hormone receptor-positive, HER2-negative locally recurrent or metastatic BC (mBC).
Journal ArticleDOI
KIF14 Promotes AKT Phosphorylation and Contributes to Chemoresistance in Triple-Negative Breast Cancer
Stina M. Singel,Crystal Cornelius,Elma Zaganjor,Kimberly Batten,Venetia R. Sarode,Dennis L. Buckley,Yan Peng,George B. John,Hsiao C. Li,Navid Sadeghi,Woodring E. Wright,Lawrence G. Lum,Timothy W. Corson,Jerry W. Shay +13 more
TL;DR: Findings show an early and critical role for Kif14 in the tumorigenic potential of TNBC, and therapeutic targeting of KIF14 is feasible and effective for TNBC.